Literature DB >> 33221398

Artificial liver support system in pediatric acute liver failure due to mushroom poisoning: Case series.

Chun-Feng Yang1, Zhen Zhang1, Xiao-Yan Zhang1, Yu-Mei Li2.   

Abstract

Pediatric acute liver failure (PALF) due to mushroom poisoning is a rare and life-threatening disease. There is no specific treatment. Plasma exchange (PE) is often used as a bridge to the regeneration of the liver or transplantation. However, PE is limited due to an inadequate plasma supply and transfusion-related risks. The double plasma molecular adsorption system (DPMAS) can adsorb toxins, including bilirubin and inflammatory mediators. However, the DPMAS cannot improve coagulation disorders. Combining PE and the DPMAS could compensate for the shortcomings of the two techniques. A previous study showed that the combination might be more effective than using PE or the DPMAS alone in patients with mild acute-on-chronic liver failure. To the best of our knowledge, few studies combined PE and the DPMAS for the treatment of PALF due to mushroom poisoning. Here, we specifically describe our experience with PE and the DPMAS in PALF. In conclusion, our study shows that the DPMAS and PE are safe and effective in reducing the bilirubin level and improving blood coagulation in PALF due to mushroom poisoning as a bridge to transplantation or recovery.
Copyright © 2020 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Double plasma molecular adsorption system; Mushroom poisoning; Pediatric acute liver failure; Plasma exchange; Treatment

Mesh:

Substances:

Year:  2020        PMID: 33221398     DOI: 10.1016/j.aohep.2020.100290

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  1 in total

1.  Multi-Functional Hypercrosslinked Polystyrene as High-Performance Adsorbents for Artificial Liver Blood Purification.

Authors:  Yunhong Liu; Xinyan Peng
Journal:  Front Chem       Date:  2022-01-17       Impact factor: 5.221

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.